2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.
Nature. 2019;572(7768):254-259.
The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M, Steinle A.
Expert Opin Ther Targets. 2019;23(4):281-294.
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
Lazarova M, Steinle A.
Front Immunol. 2019;10:2689. Review.
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
Salomé B, Gomez-Cadena A, Loyon R, Suffiotti M, Salvestrini V, Wyss T, Vanoni G, Ruan DF, Rossi M, Tozzo A, Tentorio P, Bruni E, Riether C, Jacobsen EM, Jandus P, Conrad C, Hoenig M, Schulz A, Michaud K, Della Porta MG, Salvatore S, Ho PC, Gfeller D, Ochsenbein A, Mavilio D, Curti A, Marcenaro E, Steinle A, Horowitz A, Romero P, Trabanelli S, Jandus C.
Blood Adv. 2019;3(22):3674-3687.